



September 1, 2006

IMPORTANT NOTICE
CARDENE® SR
(nicardipine HCl)
SUSTAINED RELEASE CAPSULES

CARDENE®
(nicardipine HCl)
CAPSULES

Dear Customer:

Please be advised that effective September 1, 2006, PDL BioPharma has acquired the following products from Roche:

<u>NDC</u>	<u>Product Description</u>
0004-0180-22	CARDENE® SR (nicardipine hydrochloride) Capsules, 30 mg
0004-0180-91	CARDENE® SR (nicardipine hydrochloride) Capsules, 30 mg
0004-0181-22	CARDENE® SR (nicardipine hydrochloride) Capsules, 45 mg
0004-0181-91	CARDENE® SR (nicardipine hydrochloride) Capsules, 45 mg
0004-0182-22	CARDENE® SR (nicardipine hydrochloride) Capsules, 60 mg

In order to ensure a smooth transition and avoid disruption in providing these products to the medical community and patients, we ask that you follow the procedures highlighted below.

Ordering

Roche will continue with the order management (ordering, billing, distribution, and collection functions) for Cardene SR through December 31, 2006. Once this transition period has ended, you will be able to order Cardene SR along with your other PDL BioPharma products.

Packaging

Until further notice, packaging specifications will remain unchanged.

Labeling and NDC Numbers

Cardene SR will continue to display the current Roche label and NDC numbers for the foreseeable future; PDL BioPharma will communicate new NDC numbers and labeling changes in a future memo.

Return Goods – Before December 31, 2006.

Please continue to sell all existing stock of Cardene® SR (nicardipine HCL sustained release) capsules. There is no need to return saleable inventory because of the acquisition of this product by PDL BioPharma. If your inventory is not saleable, you can return it for credit in accordance with Roche return goods policy. All returns must be made directly to:

Capital Returns
6101 N. 64th Street
Milwaukee, WI 53218
1-800-526-0625

Note: Please do not return any Cardene SR to PDL BioPharma before the end of the transition period of December 31, 2006.

Return Goods – After December 31, 2006

If your inventory is not saleable, you can return it for credit in accordance within the PDL BioPharma return goods policy,

Chargebacks

Roche will continue to process chargebacks until further notice.

Effective immediately, Roche has discontinued manufacturing of:


<u>NDC</u>	<u>Product Description</u>
0004-0183-01	CARDENE® (nicardipine hydrochloride) Capsules, 20 mg
0004-0184-01	CARDENE® (nicardipine hydrochloride) Capsules, 30 mg

Please continue to sell all existing stock of the two CARDENE® products listed above until your inventories have been depleted as returns to reduce inventory will not be accepted.

If you have any questions, please contact the Roche Customer Service Department at: 1-800-526-0625.

Roche and PDL BioPharma thank you in advance for your support and cooperation during this period.

Sincerely,



Patrick A. Cofone
Director Trade and Professional Relations
Hoffmann-La Roche, Inc. (Roche)



Rich Greene
Dir., Trade Relations/GPO/Gov't Accounts
PDL BioPharma